June 3rd, 2011 - Dualsystems and Bulldog Bio Ink Deal to Exclusive Partnership in the USA
Dualsystems Biotech, a leading developer of protein-interaction discovery tools, and Bulldog Bio, a marketing-based US distributor, have agreed to a long-term relationship to sell Dualsystems’ extensive line of protein expression and analysis systems. The partnership will establish Bulldog Bio as the single source for all of Dualsystem’s products in the US.
“Dualsystems Biotech is the world leader in yeast two-hybrid screening with tools to analyze most classes of proteins in a living cell milieu. We are very excited to broaden the awareness and expand the use of their elegant systems for identifying de novo targets for proteins of interests. Their products allow effective screening of expressed cDNA libraries to detect specific interactors of nuclear, membrane and cytosolic proteins,” says Ella Fontaine, V.P. of Communications for Bulldog Bio. She further elaborates “We feel these technologies allow scientists and R&D teams to answer important, yet difficult questions in proteomics and cell function. It will be our job to communicate and support the many uses of these technologies.”
May 13th, 2011 - Proteomics Innovation Network of Service and Product Providers Formed
ProFACT Proteomics, Inc., Monmouth Junction, NJ along with twelve other founding proteomics service and product providers have formed the Proteomics Innovation Network. The mission of the Proteomics Innovation Network is to generate “from sample to discovery” solutions in all facets of proteomics, including expression, identification, characterization, interaction and function. Each member organization has complementary expertise, core technologies, and infrastructure to address critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring. read more
May 9th, 2011 - Dualsystems Biotech announces drug profiling agreement with PTC Therapeutics
Dualsystems Biotech today announced a drug profiling agreement with US-based PTC Therapeutics, Inc. Under the agreement, Dualsystems Biotech will use its drug profiling platform to identify molecular targets for an undisclosed small molecule candidate of PTC Therapeutics’ development pipeline. read more
February 3, 2011 - Dualsystems Biotech announces 3 year project to investigate fibrodysplasia ossificans progressiva
Dualsystems Biotech announced today that it has obtained funding to carry out a 3 year project to investigate the molecular mechanisms underlying Fibrodysplasia ossificans progressive (FOP, Münchmeyer syndrome). read more
November 25, 2010 - Dualsystems Biotech AG announces the appointment of Dr. Jan zur Hausen to its Board of Directors
Dualsystems Biotech announced today that Dr. Jan zur Hausen will join its Board of Directors. read more
November 29, 2007 - Dualsystems Biotech completes CHF 2.2M financing
round
Dualsystems Biotech AG, a Zurich-based biotechnology company marketing
custom services and products for the Functional Proteomics market has announced
today that it has successfully completed its CHF 2.2M financing round. read more
April, 2004 - KTI success story: a profile on the activities of Dualsystems Biotech
Brewers’ Yeast Shows the Way to New Drugs - Two molecular biologists at Zurich University have set up their own company to market worldwide their innovative screening system for the identification of protein interactions in cell membranes.read more
